Fifteen patients (11 acute lymphoblastic leukaemia [ALL] , 3 acute myeloid leukaemia [AML] , and 1 hepatosplenic gamma/delta T-cell lymphoma and bone marrow involvement) were treated between October 2006 and May 2009 (Table I ). The median age of the patients was 11.4 years (including 3 infants). The median number of regimens administered before CCE was 2; 4 patients had received allogeneic haematopoietic stem cell transplantation (HSCT). Thirteen patients had morphologically detectable disease and 2 had persistent minimal residual disease (MRD). Drugs were administered intravenously once daily for 5 consecutive days: clofarabine at 30 to 40 mg/m 2 , cyclophosphamide at 300 to 440 mg/m 2 , and etoposide at 100 mg/m 2 . All patients received all planned doses of CCE. Patients were eligible for HSCT after CCE if a suitable donor was available. Otherwise, subsequent courses of CCE or alternative salvage therapy were given. All patients received prophylactic antibiotics (either vancomycin plus fluoroquinolone or single-agent cefepime) and an antifungal agent (voriconazole or micafungin) during periods of neutropenia. Voriconazole was held from 48 h before to 24 h after the CCE course. Table I summarizes the clinical course of patients. Of the 13 patients with morphologically detectable disease, 2 achieved complete remission (CR) and 1 complete remission without platelet recovery (CRp). Three patients achieved partial remission, and 7 had refractory disease. Of the 2 patients with persistent MRD, MRD became undetectable in 1 patient (MRD level 0.086% to <0.01%) and the disease decreased by more than 10-fold in the other (0.547% to 0.032%). Following CCE, 9 patients received HSCT at a median time interval of 85 days (range, 28-288 days). Of these, 2 who underwent HSCT after achieving CR or CRp with CCE are alive in CR (follow-up; 91 and 101 weeks, respectively), 3 died of disease relapse after HSCT, and 4 died from post-HSCT complications while in CR. Five of the 6 patients who did not receive HSCT died of disease, and one died of treatment-related complications.
Adverse events during cycle 1 are listed in Table II . Transient elevation of liver enzymes, febrile neutropenia, anorexia, and nausea were common. The only death that could be attributable to therapy was of a 17-year-old patient with B-precursor ALL and a germline TP53 mutation who had relapsed after HSCT 7.8 months earlier and whose disease was refractory to anti-CD22 immunotoxin. She experienced grade 4 hyperbilirubinaemia on day 15 of treatment without clinical features of veno-occlusive disease and died of a mucormycosis and multi-organ failure on day 30 (Tables I and II) . Two additional patients had fungal infections: candidaemia (Candida albicans) and a skin mould infection (Macrophomina phaseolina).
Pretreatment with clofarabine may suppress the repair of DNA damage caused by cyclophosphamide and etoposide, and these 3 drugs may act synergistically (Yamauchi et al, 2001 ). CCE at 40, 440, and 100 mg/m 2 , respectively, once daily for 5 days, was recommended in a Phase I study for children with refractory or relapsed leukaemia (Hijiya et al, 2009 ). All 25 patients received granulocyte-colony stimulating factor (G-CSF). Use of prophylactic antibiotics was left to the physician's discretion. Four patients had dose reductions or interruptions. Febrile neutropenia, increased aspartate transaminase and alanine transaminase, and hyperglycaemia were common, and 1 patient died of Micrococcus meningitis. In the Phase II study, 4 of the first 8 patients experienced severe hepatotoxicity (3 veno-occlusive disease and 1 hyperbilirubinaemia), which was considered to be associated with prior HSCT or concurrent infections (Hijiya et al, 2009) . Locatelli et al (2009) used CCE at 40, 400, and 150 mg/m 2 , respectively. All 25 patients were hospitalized for the duration of treatment, and 23 remained in-patients until haematological recovery. All patients received prophylaxis with acyclovir, ciprofloxacin, or amoxicillin conjugated with clavulanic acid, and voriconazole or fluconazole. The most common side effects were reversible hepatotoxicity and febrile neutropenia. In that report, there was no discontinuation of treatment due to adverse events, death from treatment-related complications, or cases of veno-occlusive disease.
The toxicity profile observed in our study is similar to that reported by Locatelli et al (2009) . In both studies, the majority of patients did not receive G-CSF. However, stringent supportive care, including prophylactic antibiotics and antifungals, is advised. We have previously reported that anti-bacterial and -fungal prophylaxis during intensive treatment of children with AML reduces episodes of infection and hospitalization (Kurt et al, 2008) , which was successfully applied in the current study. Although there were 3 cases of fungal infections, there was no case of bacteraemia. After administration of CCE, our patients were hospitalized only for medical reasons.
Recently, O'Conner et al (2011) reported 3 CRs in 5 infants with MLL rearrangement treated with single-agent clofarabine (3 patients) or CCE (2 patients). In their study, CCE was dosed based on infant weight. In our current frontline ALL protocol, Total XVI, infants with MLL rearrangement receive CCE at doses based on body surface area, as demonstrated feasible in this study. We reduce CCE doses by 50% in only infants less than 1 month of age and those who are less than 3 months of age and born significantly prematurely. In addition, patients with persistent or pre-HSCT MRD have worse prognosis (Bader et al, 2009 , Coustan-Smith et al, 2000 and may benefit from non-cross-resistant chemotherapeutic agents. We are also studying the efficacy of CCE to reduce MRD prior to HSCT for high-risk ALL patients in first remission. For patients with relapsed or refractory leukaemia, we are testing the safety of a conditioning regimen with CCE followed by Natural Killer-cell infusion from a haploidentical donor.
In summary, CCE is well tolerated and effective in children with relapsed or refractory haematological malignancies. Appropriate supportive care should be implemented. 
